COMMUNIQUÉS West-GlobeNewswire
-
BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA OPERATIONS, LLC. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
23/08/2024 - 16:00 -
Wendy Vlieks Appointed as President of The Genome Partnership, Succeeding Leisa Zigman
23/08/2024 - 16:00 -
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
23/08/2024 - 15:01 -
OKYO Pharma CEO Interview to Air on Bloomberg TV
23/08/2024 - 15:00 -
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
23/08/2024 - 14:30 -
Le KFSHRC établit de nouvelles normes mondiales en matière de technologie de RV à l’occasion de la conférence AMEE 2024
23/08/2024 - 14:15 -
WORK Medical Technology Group LTD Announces Pricing of Initial Public Offering
23/08/2024 - 14:00 -
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
23/08/2024 - 13:30 -
Repligen Corporation to Present at Wells Fargo Healthcare Conference
23/08/2024 - 13:30 -
OKYO Pharma Announces Chairman Acquires Shares
23/08/2024 - 13:00 -
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
23/08/2024 - 13:00 -
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
23/08/2024 - 13:00 -
KFSHRC Empowers Future Healthcare Leaders with Innovative Research Programs
23/08/2024 - 11:46 -
PCI Biotech: Invitation to first half interim 2024 results presentation
23/08/2024 - 09:36 -
Vistin Pharma ASA: Second quarter and first half 2024 financial results
23/08/2024 - 07:40 -
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
23/08/2024 - 07:00 -
Burning Rock Reports Second Quarter 2024 Financial Results
23/08/2024 - 05:59 -
Brains Bioceutical s’apprête à obtenir l’une des premières certifications CEP pour le cannabidiol au monde auprès de la Direction européenne de la qualité du médicament et soins de santé
23/08/2024 - 04:06 -
NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report
22/08/2024 - 22:40
Pages